Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update
Although survival of multiple myeloma patients has at least doubled during recent years,
most patients eventually relapse, and treatment at this stage may be particularly complex. At …
most patients eventually relapse, and treatment at this stage may be particularly complex. At …
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia
SP Treon, L Xu, G Yang, Y Zhou, X Liu… - … England Journal of …, 2012 - Mass Medical Soc
Background Waldenström's macroglobulinemia is an incurable, IgM-secreting
lymphoplasmacytic lymphoma (LPL). The underlying mutation in this disorder has not been …
lymphoplasmacytic lymphoma (LPL). The underlying mutation in this disorder has not been …
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia
Waldenström macroglobulinemia (WM) is a B-cell disorder characterized by the infiltration
of lymphoplasmacytic cells into bone marrow and the presence of an IgM monoclonal …
of lymphoplasmacytic cells into bone marrow and the presence of an IgM monoclonal …
The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic …
The genetic basis for Waldenström macroglobulinemia (WM) remains to be clarified.
Although 6q losses are commonly present, recurring gene losses in this region remain to be …
Although 6q losses are commonly present, recurring gene losses in this region remain to be …
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional …
By whole-genome and/or Sanger sequencing, we recently identified a somatic mutation
(MYD88 L265P) that stimulates nuclear factor κB activity and is present in> 90% of …
(MYD88 L265P) that stimulates nuclear factor κB activity and is present in> 90% of …
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia
G Yang, Y Zhou, X Liu, L Xu, Y Cao… - Blood, The Journal …, 2013 - ashpublications.org
Abstract Myeloid differentiation factor 88 (MYD88) L265P somatic mutation is highly
prevalent in Waldenström macroglobulinemia (WM) and supports malignant growth through …
prevalent in Waldenström macroglobulinemia (WM) and supports malignant growth through …
MYD88 L265P mutation in Waldenstrom macroglobulinemia
S Poulain, C Roumier, A Decambron… - Blood, The Journal …, 2013 - ashpublications.org
Mutation of the MYD88 gene has recently been identified in activated B-cell–like diffuse cell
lymphoma and enhanced Janus kinase/signal transducer and activator of transcription (JAK …
lymphoma and enhanced Janus kinase/signal transducer and activator of transcription (JAK …
The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's …
CXCR4 WHIM somatic mutations are common Waldenstrom's Macroglobulinemia (WM), and
are associated with clinical resistance to ibrutinib. We engineered WM cells to express the …
are associated with clinical resistance to ibrutinib. We engineered WM cells to express the …
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
Detailed genomic studies have shown that cytogenetic abnormalities contribute to multiple
myeloma (MM) pathogenesis and disease progression. Nevertheless, little is known about …
myeloma (MM) pathogenesis and disease progression. Nevertheless, little is known about …
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma
The CXC chemokine receptor type 4 (CXCR4) plays a crucial role in modulating cell
trafficking in hematopoietic stem cells and clonal B cells. We screened 418 patients with B …
trafficking in hematopoietic stem cells and clonal B cells. We screened 418 patients with B …